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Abstract Beta-carotene 15,150-monooxygenase 1 knock-
out (Bcmo1-/-) mice accumulate beta-carotene (BC)
similarly to humans, whereas wild-type (Bcmo1?/?) mice
efficiently cleave BC. Bcmo1-/- mice are therefore suitable
to investigate BC-induced alterations in gene expression in
lung, assessed by microarray analysis. Bcmo1-/- mice
receiving control diet had increased expression of
inflammatory genes as compared to BC-supplemented
Bcmo1-/- mice and Bcmo1?/? mice that received either
control or BC-supplemented diets. Differential gene
expression in Bcmo1-/- mice was confirmed by real-time
quantitative PCR. Histochemical analysis indeed showed an
increase in inflammatory cells in lungs of control Bcmo1-/-
mice. Supported by metabolite and gene-expression data, we
hypothesize that the increased inflammatory response is due
to an altered BC metabolism, resulting in an increased
vitamin A requirement in Bcmo1-/- mice. This suggests that
effects of BC may depend on inter-individual variations in
BC-metabolizing enzymes, such as the frequently occurring
human polymorphisms in BCMO1.
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Introduction
Beta-carotene (BC) is an orange-colored dietary com-
pound present in various fruits and vegetables. BC is
regarded as an active antioxidant and is thus able to
diminish radical-induced macromolecular damage [1].
Because of this, a high intake of BC might be expected to
be beneficial, and indeed epidemiological studies have
shown that a high dietary intake of BC is associated with
a lower risk for cardiovascular diseases and several types
of cancer, including lung cancer [2, 3]. Moreover, BC can
be metabolized into vitamin A, thereby preventing vita-
min A deficiency. Vitamin A deficiency can result in
a wide variety of clinical manifestations, ranging from
night blindness, growth abnormalities, an increased
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susceptibility for infections, as well as an increased
mortality due to infectious diseases [4, 5]. In Western
society, smokers are at risk for vitamin A deficiency in
the lung [6, 7]. Since dietary BC intake is able to prevent
vitamin A deficiency and is associated with a decreased
lung cancer risk, it was hypothesized that BC supple-
mentation in smokers would be beneficial and would
decrease lung cancer incidence. In contrast to this
expectation, BC supplementation alone (ATBC study, [8])
or in combination with vitamin E (CARET study, [9])
resulted in an increased lung cancer risk in smokers and
asbestos-exposed subjects [8, 9]. An increased lung can-
cer risk was predominantly observed in smokers and
asbestos-exposed subjects and not in former or non-
smokers [10, 11]. Moreover, a 6-year follow-up of the
CARET study revealed that females were more at risk for
the development of lung cancer upon BC supplementation
compared to male volunteers [12]. The underlying
mechanisms are not precisely known, although several
mechanisms have been suggested. Possibly, BC or BC
metabolites can become pro-oxidants at high concentra-
tions [13] or in combination with oxidative stress [14].
There is also evidence that BC supplementation can result
in a changed regulation of the transcription factor retinoic
acid receptor (RAR) [15]. However, the exact mechanism
behind the possible adverse effect of a high BC intake is
still poorly understood.
An important drawback in BC research is BC metab-
olism. First of all, BC metabolism in humans is highly
variable [16, 17] and most of this variability can be
attributed to differences in enzymatic activity of the beta-
carotene 15,150-monooxygenase 1 enzyme (BCMO1). The
267A[T and 379C[T polymorphisms in the BCMO1
gene are common with variant allele frequencies of 42
and 24%, respectively, in Caucasian population of the
United Kingdom, and result in increased BC and
decreased BC metabolite concentrations in plasma [18,
19]. Secondly, inter-species differences, especially in
Bcmo1 activity, are the cause of the great differences in
BC-metabolizing activity between humans and regularly
used laboratory rodents. Rodents have a more active
Bcmo1 enzyme variant than humans [20], and therefore
BC supplementation to rodents results in a virtually
complete conversion of BC and consequently in a high
concentration of BC metabolites. Previously, a Bcmo1
knockout (Bcmo1-/-) mouse was established and char-
acterized, and BC supplementation to these Bcmo1-/-
mice resulted in increased BC plasma concentrations and
BC accumulation in mouse lung tissue [21]. This
Bcmo1-/- mouse is therefore a unique model to investi-
gate the effects of BC itself.
The aim of our study was to investigate BC-induced
gene-expression differences. Therefore, female Bcmo1?/?
and Bcmo1-/- mice, unable to symmetrically cleave BC,
were fed for 14 weeks with a vitamin A-sufficient diet
(1,500 IU/kg) without (control) or with supplementation of
BC (BC, 150 mg/kg diet) and microarray analysis was
performed (whole-mouse genome arrays) on lung copy
RNA (cRNA). We specifically chose female animals
because the effects of BC were more pronounced and
longer-lasting in female volunteers of the CARET study
[12]. Moreover, wild-type (Bcmo1?/?) mice were analyzed
to distinguish BC-induced effects from the effects due to
the knockout of the Bcmo1 gene.
Materials and methods
Animals and treatment
Twelve female (Fe) B6129SF1 (Bcmo1?/?) and 12 female
B6;129S-Bcmo1tm1dnp (Bcmo1-/-) mice, previously
described by Hessel et al. [21] were used for the experi-
ment. The mouse experiment was conducted in accordance
with German animal protection laws by the guidelines of
the local veterinary authorities. During the breeding and
weaning periods of the mice, mothers were maintained on
KLIBA 3430 chow containing 14,000 IU vitamin A/kg
diet (Provima Kliba AG, Kaiseraugst, Switzerland). Five-
week-old female Bcmo1?/? and Bcmo1-/- mice were
caged in groups containing 2–4 siblings per group and were
maintained under environmentally controlled conditions
(temperature 24C, 12 h/12 h light–dark cycle). Mice had
ad libitum access to feed and water. Basic feed consisted of
the palletized diet D12450B (Research Diets Inc, USA)
with a fat content of 10%. The diet was modified to contain
1,500 IU vitamin A/kg of diet, which is a vitamin A-suf-
ficient diet, and the control diet was supplemented with
water-soluble vehicle beadlets (DSM Nutritional Products
Ltd., Basel, Switzerland) containing DL-alpha-tocopherol
and ascorbyl palmitate as stabilizers, as well as carriers
such as gelatine, corn oil sucrose, and starch. The BC diet
was supplemented with identical water-soluble beadlets
containing 10% BC (DSM Nutritional Products Ltd., Basel,
Switzerland) to generate 150 mg BC/kg diet. Beadlets
were added by the manufacturer before low-temperature
pelletting. Feed pellets were color-marked and stored at
4C in the dark.
After 14 weeks of dietary intervention, six female
Bcmo1?/? on the control diet (Bcmo1?/? Co), six female
Bcmo1?/? on the BC diet (Bcmo1?/? BC), three female
Bcmo1-/- on the control diet (Bcmo1-/- Co) and three
female Bcmo1-/- on the BC diet (Bcmo1-/- BC) were
randomly sacrificed during three subsequent mornings.
Blood was collected from the vena cava after isoflurane
and ketamine anesthesia. Blood was coagulated for at least
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20 min at room temperature, cooled to 4C, and then
centrifuged. Lung tissue was removed, rinsed in phosphate
buffered saline (PBS) and snap-frozen in liquid nitrogen.
The lung tissues were stored at -80C. Due to an insuffi-
cient number of female Bcmo1-/- mice in the original
breeding pool, female Bcmo1-/- mice were used that were
born 2 weeks later from an identical experiment, treated
identically with three mice on the control diet and three
mice on the BC diet to generate n = 6 per group, and
sacrificed 2 weeks after the first group of mice.
HPLC separation of retinoids and carotenoids
Retinoids and carotenoids were extracted from lung tissues
and plasma under dim red safety light (k C 600 nm).
Briefly, tissues (20–40 mg) were homogenized in 200 ll of
2 M hydroxylamine (pH 6.8) and 200 ll of methanol with
a glass homogenizer. For determination of BC and retinol
in serum, 180 ll serum was added to 200 ll methanol.
Then 400 ll acetone was added either to these plasma or
tissue extracts. Extraction of carotenoids and retinoids was
performed with petroleum ether. The extraction was repe-
ated three times, and the collected organic phases were
dried under nitrogen and redissolved in HPLC solvent
(n-hexane/ethanol, 99.5:0.5). HPLC separation of carote-
noids and retinoids and quantification of peak integrals was
performed as previously described [22]. Solvents for HPLC
and extraction were purchased in HPLC grade from Merck
(Darmstadt, Germany).
Serum analysis of inflammation markers
Serum levels of the inflammatory cytokines; tumor necro-
sis factor alpha (TNF-a), interleukin-6 (IL-6) and
monocyte chemoattractant protein-1 (MCP-1) were mea-
sured using the mouse serum adipokine Lincoplex Kit
(Linco Research, Nuclilab, Ede, The Netherlands). Sera
were diluted four times in HPE buffer (Sanquin, Amster-
dam, The Netherlands) and measured according to the
manufacturer’s protocol and as described before [23].
Cytokine levels were measured using the Bio-Plex system
(Bio-Rad, Veenendaal, The Netherlands) and using Bio-
Plex software (Bio-Rad). All individual samples were
analyzed in duplicate and averaged. The detection limit of
MCP-1 was 60 pg/ml, of IL-6 was 5 pg/ml, and of TNF-a
was 0.3 pg/ml.
Histology of the lung
Small pieces of upper-right-lung tissue of two randomly
selected animals per group were fixed by immersion in 0.1 M
sodium phosphate buffer containing 4% paraformaldehyde
(pH 7.4) overnight at 4C, thereafter dehydrated, cleared,
and then paraffin-embedded. Three lm-thick sections were
cut and stained with periodic acid schiff (PAS) and Mayer’s
hematoxylin for histological analysis.
RNA isolation
Left-lung lobes were homogenized in liquid nitrogen using
a cooled mortar and pestle. Total RNA was isolated using
TRIzol reagent (Invitrogen, Breda, The Netherlands) fol-
lowed by purification using RNeasy columns (Qiagen,
Venlo, The Netherlands) using the instructions of the
manufacturer. RNA concentration and purity were mea-
sured using the Nanodrop system (IsoGen Life Science,
Maarsen, The Netherlands). Approximately 30 lg of total
RNA was isolated with A260/A280 ratios above 2 and A260/
A230 ratios above 1.9 for all samples, indicating good RNA
purity. RNA degradation was checked on the Experion
automated electrophoresis system (Bio-Rad, Veenendaal,
The Netherlands) using Experion StdSense chips (Bio-
Rad). Two samples did not meet RNA quality (Bcmo1?/?
mice, one on BC diet and one on control diet) and were
omitted from the experiment.
Microarray hybridization procedure
The 4 9 44 k Agilent whole-mouse genome microarrays
(G4122F, Agilent Technologies, Inc., Santa Clara, CA)
were used. Preparation of the sample and the microarray
hybridization were carried out according to the manufac-
turer’s protocol with a few exceptions as described
previously [23, 24]. In brief, cDNA was synthesized from
1 lg lung RNA using the Agilent Low-RNA Input Fluo-
rescent Linear Amplification Kit for each animal without
addition of spikes. Thereafter, samples were split into two
equal amounts, to synthesize Cyanine 3-CTP (Cy3) and
Cyanine 5-CTP (Cy5) labeled cRNA using half the
amounts per dye as indicated by the manufacturer (Agilent
Technologies). Labeled cRNA was purified using RNeasy
columns (Qiagen). Yield, A260/A280 ratio and Cy3 or Cy5
activity were examined for every sample using the nano-
drop. All samples met the criteria of a cRNA yield higher
than 825 ng and a specific activity of at least 8.0 pmol Cy3
or Cy5. Then, 1,200 ng of every Cy3-labeled cRNA sam-
ple was pooled and used as a common reference pool.
Individual 825-ng Cy5-labeled cRNA and 825-ng pooled
Cy3-labeled cRNA were fragmented in 19 fragmentation
and 19 blocking agent (Agilent Technologies) at 60C for
30 min and thereafter mixed with GEx Hybridization
Buffer HI-RPM (Agilent Technologies) and hybridized in a
1:1 ratio at 65C for 17 h in the Agilent Microarray
Hybridization Chamber rotating at 4 rpm. After hybrid-
ization, slides were washed according to the wash protocol
with Stabilization and Drying solution (Agilent
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Technologies). Arrays were scanned with an Agilent
scanner with 10 and 100% laser-power intensities (Agilent
Technologies).
Data analyses of microarray results
Signal intensities for each spot were quantified using
Feature Extraction 9.1 (Agilent Technologies). Median
density values and background values of each spot were
extracted for both the experimental samples (Cy5) and the
reference samples (Cy3).
Quality control for every microarray was performed
visually by using ‘Quality’ control graphs from ‘Feature’
extraction and M-A plots and boxplots, which were made
using limmaGUI in R (Bioconductor) [25]. Data were
imported into GeneMaths XT 2.0 (Applied Maths, Sint-
Martens-Latem, Belgium). Spots with a Cy5 and Cy3
signal twice above background were selected and log-
transformed. The Cy5 signal was normalized against the
Cy3 intensity as described before [26]. Supervised princi-
pal component analysis and heat mapping were performed
using GeneMaths XT. Volcano plots were made using
GraphPad Prism 5.0. Pathway analysis was performed
using MetaCore (GeneGo), GO overrepresentation analysis
(ErmineJ) [27] and literature mining.
Analysis of mRNA expression by real-time quantitative
PCR (Q-PCR)
Real-time quantitative PCR (Q-PCR) was performed on
individual samples (n = 6 per group) as previously
described [28] to validate the microarray data. One
microgram of RNA of all individual samples was used for
cDNA synthesis using the iScript cDNA synthesis kit (Bio-
Rad). Q-PCR reactions were performed with iQ SYBR
Green Supermix (Bio-Rad) using the MyIQ single-color
real-time PCR detection system (Bio-Rad). Each reaction
(25 ll) contained 12.5 ll iQ SYBR green supermix, 1 ll
forward primer (10 lM), 1 ll reverse primer (10 lM),
8.5 ll RNase-free water and 2 ll diluted cDNA. The
following cycles were performed: 1 9 3 min at 95C, 40
amplification cycles (40 9 15 s 95C, 45 s optimal
annealing temperature, which was followed by 1 9 1 min
95C and 1 9 1 min 65C and a melting curve was pre-
pared (60 9 10 s 65C with an increase of 0.5C per 10 s).
A negative control without cDNA template and a negative
control without reverse transcriptase (-RT) were taken
along with every assay. Data were normalized against the
reference genes syntaxin 5a (Stx5a) and ring finger protein
130 (Rnf130), which were chosen based on stable gene-
expression levels between the mice on the microarray.
Primers were designed using Beacon designer 7.00 (Pre-
mier Biosoft International, Palo Alto, CA). The following
primer sequences were used; reference gene Stx5a form-
ward 50-TTAAAGAACAGGAGGAAACGATTCAGAG-
30 and reverse 50-CAGGCAAGGAAGACCACAAAGA
TG-30 (PCR at 60.0C), reference gene Rnf130 forward
50-ACAGGAACCAGCGTCGTCTTG-30 and reverse
50-ACCCGAACAACATCATTCTGCTTATAG-30 (PCR at
60.0C), interferon, alpha-inducible protein 27 (Ifi27)
forward 50-GCTGCTACCAGGAGGACTCAAC-30 and
reverse 50- TGCTGATTGGAGTGTGGCTACC-30 (PCR
at 59.2C), tripartite motif protein 12 (Trim12) forward
50-GGAGAACATCATAGAACGGAGTCATAC-30 and
reverse 50- GGAAGACCCCTAGTAGCGATGAG-30
(PCR at 58.3C), ISG15 ubiquitin-like modifier (Isg15)
forward 50-TGCAGCAATGGCCTGGGAC-30 and reverse
50-GCGCTGCTGGAAAGCCG-30 (PCR at 58.3C), inter-
feron-induced protein 44 (Ifi44) forward 50- AGAC
TTGATAAAACATGGCATTCTGC-30 and reverse 50-
CATGGAATGCCTCCAGCTTGG-30 (PCR at 58.3C). A
standard curve for all genes, including reference genes, was
generated using serial dilutions of a pooled sample (cDNA
from all reactions of the groups analyzed). mRNA levels
were determined using the DDCT method (IQ5 software
version 2.0; Bio-Rad). Analysis of individual samples was
performed in duplicate.
Statistical analysis
Fold changes for both microarray gene expression and
Q-PCR gene expression were calculated using mean log
signal intensities. P values for differential expressions were
calculated between two groups using two-tailed Student’s t
test statistics on log intensity values. Changes were con-
sidered statistically different at p \ 0.05. Effects of diet
and genotype on concentrations of BC, retinol, and retinyl
esters in lung and serum were analyzed using 2 9 2 fac-
torial univariate ANOVA (SPSS version 15.0) and
considered statistically significant when p \ 0.05. Corre-
lations and differences in correlations between BC
concentration and BC metabolite concentrations in lung
were tested (SPSS) and considered significant when
p \ 0.05.
Results
BC supplementation results in an increased BC
concentration in lungs, particularly in Bcmo1-/- mice
BC supplementation resulted in elevated BC levels in
serum and lung tissue of all mice (p \ 0.05), but to a
higher extent in Bcmo1-/- mice (Fig. 1a, b, p \ 0.05).
Retinol serum levels were not significantly different
between the groups (Fig. 1c). Retinol and retinyl ester
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concentrations in lung were increased in all mice upon BC
supplementation (p \ 0.05), and as expected, to a higher
extend in Bcmo1?/? (Fig. 1d, e).
BC supplementation to Bcmo1-/- mice restores
differential gene expression to levels as observed
in Bcmo1?/? mice
To investigate the effects of BC on lung gene expression,
microarray analysis was performed on cRNA of all mice.
Of the 43,379 spots (number of spots on array minus
control spots), 31,128 had a signal twice above background
and were regarded as positive spots and included in the
analysis. Supervised principal component analysis (SPCA)
showed that animals could be discriminated according to
their Bcmo1 genotype and diet (Fig. 2a). BC supplemen-
tation resulted in 651 and 1,522 differentially expressed
genes (p \ 0.05) in the Bcmo1?/? and Bcmo1-/- mice,
respectively. Of these BC-regulated genes, 32 were
commonly regulated in Bcmo1?/? and Bcmo1-/- mice and
thus regulated independent of genotype.
We were interested in the effects resulting from BC
accumulation in lung tissue. Since BC levels in lung tissue
were higher in Bcmo1-/- mice than in Bcmo1?/? mice and,
correspondingly, more genes were regulated in this group
after BC supplementation, we further focused on effects of
BC in Bcmo1-/- mice. Of the 1,522 BC-regulated genes in
the Bcmo1-/- mice, 121 had an absolute fold-change
(FC) [1.5-fold, with mainly down-regulated genes
(Fig. 2b). We continued with these 121 BC-regulated genes
and investigated whether these genes were regulated due to
an effect of BC treatment in Bcmo1-/- mice or due to an
effect in the Bcmo1-/- control mice. Therefore, we eval-
uated gene expression of these 121 genes in all four groups;
Bcmo1?/? control mice, Bcmo1?/? mice with supplemen-
tation of BC, Bcmo1-/- control mice and Bcmo1-/- mice
with BC supplementation. The absolute expression of each
of the 121 genes was set on one for the Bcmo1?/? control
Fig. 1 BC and BC metabolite
concentration in lungs of female
Bcmo1-/- and Bcmo1?/? mice.
Beta-carotene (BC) (a, b) and
retinol (c, d) concentrations in
serum and in lung tissue,
respectively, and retinyl ester
concentrations in lung tissue
(e) of female Bcmo1?/? mice
and Bcmo1-/- mice fed a
control diet (white bars) or a
BC-supplemented diet (black
bars). Data are expressed as
mean ± SEM, significance was
tested using ANOVA and
considered significant at
p \ 0.05. D effect of diet,
G effect of genotype, D 9 G
interaction between diet and
genotype. Student’s t test was
performed between the BC and
control diet and considered
significant at p \ 0.05.
*p \ 0.05, **p \ 0.01 and
***p \ 0.001
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mice. Cluster analysis of the expression of these genes
showed that the Bcmo1-/- control mice differed most in
gene expression compared to the other three groups
(Fig. 3a). The expression of these genes was compared to
the expression in the Bcmo1?/? control mice and revealed
that the average absolute fold-change was significantly
different in the Bcmo1-/- control mice compared to the
Bcmo1?/? control mice (p \ 0.001), while there was no
difference between the average expression of these 121
genes between the BC-supplemented Bcmo1-/- mice or
Bcmo1?/? mice and the Bcmo1?/? control mice (Fig. 3b).
A
B
Fig. 2 Supervised principal component analysis and volcano plot of
the microarray data. a Supervised principal component analysis
(SPCA) of the four groups; Bcmo1?/? control mice (open circles),
Bcmo1?/? BC mice (closed circles), Bcmo1-/- control mice (open
squares), and Bcmo1-/- BC mice (closed squares). Bcmo1?/? mice
are separated from Bcmo1-/- mice (x-axis) and mice on control diet
are separated from mice on the BC diet (y-axis). b Volcano plot of the
effect of BC supplementation on gene expression in Bcmo1-/- mice,
showing the fold-change on the x-axis and the corresponding
Student’s t test p value on the y-axis. In black are all the genes
with a p value \ 0.05 and an absolute fold-change [ 1.5. Trim12
with a FC of 8.75 and p \ 0.05 is outside the limits of this figure
Fig. 3 Relative expression of genes regulated by BC in Bcmo1-/-
mice in all groups. a Hierarchical clustering of all experimental
groups based on the expression of all genes regulated by BC in the
Bcmo1-/- mice with an absolute FC [ 1.5 and p \ 0.05. The
expression of every gene is represented relative to the expression in
Bcmo1?/? control mice, which was set to 1.0. Genes and groups were
clustered using Euclidean distance (linear scaled) UPGMA. b Graph
representing the expression level of all genes regulated by BC in the
Bcmo1-/- mice with an absolute FC [ 1.5 and p \ 0.05, in all
groups. The expression of every gene is represented relative to the
expression in Bcmo1?/? control mice, which was set to 1.0. The
absolute expression was significantly higher (p \ 0.001) in Bcmo1-/-
control mice compared to mice in the other groups. There was no
significant difference in expression level between the other groups.
***p \ 0.001
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These data indicate that there was mainly an effect of the
knockout of the Bcmo1 gene in the mice fed the control
diet, which was returned to normal levels as observed in
the Bcmo1?/? mice by BC supplementation.
Confirmation of array results by Q-PCR
Real-time quantitative PCR (Q-PCR) was used to validate
microarray results. Genes with the highest upregulation in
Bcmo1-/- control mice compared to all other groups:
interferon-induced protein 44 (Ifi44) (Fig. 4a), and inter-
feron-induced protein 27 (Ifi27) (Fig. 4b); downregulation
in Bcmo1-/- control mice: tripartite motif-containing 12
(Trim12) (Fig. 4c), and previously demonstrated retinoic
acid responsiveness: ISG15 ubiquitin-like modifier (Isg15)
[29] (Fig. 4d) were selected for quantification. Microarray
results were confirmed by Q-PCR, resulting in a virtual
identical and significant downregulation of Ifi44, ifi27,
ISG15, and an upregulation of Trim12 in BC-supplemented
Bcmo1-/- mice compared to Bcmo1-/- control mice in
both microarray and Q-PCR analysis.
Gene expression and histology showed an increase
in inflammatory responses in lungs of Bcmo1-/-
control mice
We further classified the 121 genes that were regulated in
Bcmo1-/- control mice with an absolute FC [ 1.5 compared
to BC-supplemented Bcmo1-/- mice into general biological
process categories (Table 1). The main affected biological
process category was the immune response and in particular
direct interferon-induced gene response (Fig. 5). ErmineJ
overrepresentation analysis and MetaCore analysis also
showed that there was an overrepresentation of the inflam-
matory response in Bcmo1-/- control mice compared to
BC-supplemented Bcmo1-/- mice using the whole dataset
(ErmineJ; GO:0006954, Inflammatory response, p \ 10-7,
MetaCore; several maps belonging to the cell process
immune response, p \ 2 9 10-4).
Since most of the genes induced in Bcmo1-/- mice on
the control diet were involved in inflammatory responses,
we investigated whether the mice had an increased con-
centration of the inflammation-related cytokines: tumor
necrosis factor (TNF-a), interleukin-6 (IL-6) and monocyte
chemoattractant protein-1 (MCP-1). Serum concentrations
of all three markers were below the detection limit (data
not shown) while pulmonary infections usually would
result in detectable serum concentrations of these markers
[30].
We had additional material of two animals per group
available for morphological analysis. Paraffin-embedded
sections were stained with hematoxylin and PAS and then
analyzed. Histology showed an overall healthy lung
structure in all animals of the groups; Bcmo1?/? control
mice, Bcmo1?/? receiving BC supplementation and
Bcmo1-/- receiving BC supplementation (Fig. 6 a, b, e).
The overall lung histology of the Bcmo1-/- control mice
was however different from the other groups due to a
general increase in the number of inflammatory cells in the
lung and occasionally larger inflamed areas (Fig. 6d, e)
resembling previously described lung histology upon
vitamin A deficiency in rats [31].
Fig. 4 Confirmation of
microarray results by real-time
quantitative PCR (Q-PCR). The
expression of the genes a Ifi44,
b Ifi27, c Trim12 and d Isg15 in
Bcmo1-/- mice on a control
diet and mice supplemented
with BC as analyzed with
microarray (left) and as
analyzed by Q-PCR (right)
using stable reference genes
Stx5a and Rnf130. Data
represent the average ± SEM
with the average expression of
every gene set at 1.0 of mice fed
the control diet. *p \ 0.05 using
Student’s t test on the log-
transformed data
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Expression of genes involved in BC metabolism
are shifted towards an increased retinyl ester storage
in Bcmo1-/- mice
To further investigate whether a lack of BC or BC
metabolites could explain the transcriptional and histo-
logical increased inflammatory response in the Bcmo1-/-
control mice, we investigated changes in downstream BC
metabolism. First, we evaluated correlations between BC,
retinol and retinyl ester concentrations in mouse lung.
There was a significant positive correlation between retinyl
ester and BC concentrations in lung tissue of Bcmo1?/?
mice (R = 0.90, p \ 0.001) (Fig. 7a) with a much lower
slope in the Bcmo1-/- mice (R = 0.87, p \ 0.001). There
was no significant correlation between retinol and BC
concentrations in lung tissue of both Bcmo1?/? as well as
in Bcmo1-/- mice (R = 0.46, p = 0.13 and R = 0.52,
p = 0.10) (Fig. 7b).
Additionally, the expression of genes involved in
downstream BC metabolism and retinoic acid catabolism
in the lungs was analyzed. Four genes involved in BC
metabolism were differentially expressed in Bcmo1-/-
mice compared to the Bcmo1?/? mice (Table 2) with
lecithin-retinol acyltransferase (Lrat) and alcohol dehy-
drogenase 7 class IV (Adh7) having the highest
fold-change. The expression of Lrat, involved in the
esterification of retinol into retinyl esters to store retinol
[32], was 2.6 and 3.2 times up-regulated in Bcmo1-/- mice
on the control and BC-supplemented diet, respectively, as
compared to the Bcmo1?/? control mice. Moreover, Adh7,
the enzyme with the highest affinity and the highest con-
version rate in the metabolism of retinol into retinal [33]
was 2.7 times lower expressed in the Bcmo1-/- mice on a
control diet as compared to the Bcmo1?/? control mice. BC
supplementation of Bcmo1-/- mice partly restored this
decreased Adh7 expression.
Discussion
In this study we investigated transcriptional pathways that
are regulated by BC in vivo in the lung to obtain insight
into the possible mechanisms underlying previously found
adverse effects of BC supplementation. For this purpose,
we used a Bcmo1-/- mouse model that is known to
accumulate BC in serum and lung, as well as Bcmo1?/?
mice that have increased BC metabolite concentrations
upon BC supplementation. Lung gene expression was
explored using whole-genome microarrays and revealed
that mainly genes involved in inflammation were up-reg-
ulated in Bcmo1-/- control mice. Similarly, histological
analysis revealed an increased infiltration of inflammatory
cells in Bcmo1-/- control mice. BC supplementation ofT
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Bcmo1-/- mice restored inflammatory gene expression and
decreased the infiltration of inflammatory cells to levels
as observed in Bcmo1?/? control mice. An increased
inflammatory response in the lungs has previously been
observed upon vitamin A deficiency [34] and since
BC supplementation could reverse the increase in
Fig. 5 Biological processes
affected in Bcmo1-/- control
mice. Graph representing the
number of genes differentially
expressed in Bcmo1-/- control
mice versus Bcmo1-/- BC-
supplemented mice. p \ 0.05
and absolute fold change [ 1.5
per biological processes
category
Fig. 6 Histological analysis of
lung tissue. Representative
sections (right upper lobe) of
the lung of Bcmo1?/? mice
(a, b) and Bcmo1-/- mice (c–e)
on a control diet (a, c, d) or a
BC-enriched diet (b, e). The
lungs of Bcmo1-/- mice
receiving the control diet (c,d)
had a different appearance
compared to the lungs of the
other groups, with an increase in
inflammatory cells and
occasionally some inflamed
area’s (d). Magnification: 409
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inflammatory cells and inflammation-related gene expres-
sion, we hypothesize that these effects are due to increased
dietary vitamin A requirement in Bcmo1-/- mice com-
pared to Bcmo1?/? mice. An explanation for this increased
vitamin A requirement could lie in the altered downstream
BC and vitamin A metabolism in Bcmo1-/- mice, resulting
in a less efficient conversion of vitamin A into the bioactive
form of vitamin A; retinoic acid. BC supplementation was
able to restore these requirements despite the knockout of
Bcmo1.
We observed an increase in inflammatory cells in lung
tissue and an increase in the expression of genes involved
in inflammation in Bcmo1-/- control mice, which was
restored by BC supplementation to levels observed in
Bcmo1?/? mice. An effect of BC itself on the inflammatory
response has not been reported, whereas vitamin A defi-
ciency has been reported to increase inflammation in rats
[31, 34]. Moreover, vitamin A supplementation in vitamin
A-deficient populations reduced the number and severity of
infections and decreased the infection-induced mortality
rate [5]. Since vitamin A levels were approximately similar
in lungs of Bcmo1-/- mice fed with a control diet and
Bcmo1?/? mice, the increased inflammatory response
likely involves the bioactive vitamin A metabolite retinoic
acid. Retinoic acid is able to bind to the transcriptional
active retinoic acid receptor (RAR) or to the retinoid X
receptor (RXR), thereby modulating transcriptional
responses. Indeed, effects on the inflammatory response
have been shown to be regulated through the transcription
factor retinoic acid receptor (RAR) [35, 36]. For example,
Th1/Th2/Th17 balance, which is involved in adaptive
immune response and important in the onset of autoim-
mune diseases, asthma, and allergic diseases, has been
attributed to RAR activity. Interestingly, interferon-stimu-
lated genes, which were predominant in our study, can also
be RAR-regulated [37, 38]. Retinoic acid can be present in
two isomers; all-trans retinoic acid (atRA) and 9-cis reti-
noic acid (9cRA), which have different transcriptional
activities. Both isomers are able to bind to RAR, while only
9cRA can bind to RXR. Since effects on immunological
function have mainly been attributed to RAR functioning, a
shift in the balance of atRA and 9cRA is very unlikely to
explain our results. We explain the increase in the
inflammatory response in lungs of Bcmo1-/- mice by a
more general reduction in available retinoic acid in
Bcmo1-/- control mice due to altered gene expression of
downstream BC-metabolizing enzymes. The gene expres-
sion of Alcohol dehydrogenase 7 (class IV Adh7), a key
enzyme in the conversion of vitamin A into retinal and an
important step before the formation of biologically active
retinoic acid [39], was 2.7-fold down-regulated in
Bcmo1-/- mice compared to the Bcmo1?/? mice on the
control diet. Indeed, Adh7 activity has previously been
shown to be inversely associated with the degree of
Fig. 7 Correlation of BC and BC metabolite concentrations in lung.
Correlation of a BC concentration and retinyl ester concentration
(Bcmo1?/?: R = 0.90, p \ 0.001; Bcmo1-/-: R = 0.87, p \ 0.001)
and b BC concentration and retinol concentration (Bcmo1?/?:
R = 0.46, p = 0.13; Bcmo1-/-: R = 0.52, p = 0.10) in lungs of
Bcmo1?/? mice (open circles) and Bcmo1-/- mice (closed circles)
Table 2 Genes involved in BC metabolism and retinoic acid catabolism, which are significantly regulated by the knockout of Bcmo1
Systematic name Source symbol Bcmo1?/? Bcmo1-/-
Co BC Co BC
Aldehyde dehydrogenase family 1, subfamily A2 Aldh1a2 1a -1.03a 1.25b 1.20b
Aldehyde dehydrogenase family 1, subfamily A3 Aldh1a3 1a -1.25b -1.43c -1.41c
Aldehyde dehydrogenase 2, mitochondrial Aldh2 1a 1.05a -1.18b -1.01a
Lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) Lrat 1a 1.58b 2.58c 3.15c
Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide Adh7 1a -1.14a -2.67b -2.16c
Different letters indicate significant differences (Student’s t test, p \ 0.05)
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inflammation in the human gastric mucosa [40]. Addi-
tionally, an interaction between vitamin A concentration
and Adh7 expression was previously reported: a vitamin
A-deficient diet led to a decreased fetal survival in Adh7
knockout mice compared to wild-type mice, but not on a
vitamin A-sufficient diet [33, 41]. The 2.6-fold increase in
lecithin-retinol-O-acyltransferase (Lrat) in Bcmo1-/- mice
was also striking. Lrat is the main enzyme [32] for con-
version of retinol to retinylesters, a form in which vitamin
A can be stored, indicating that vitamin A is rather ester-
ified and stored in Bcmo1-/- lungs. Taken together, these
findings suggest that an increased inflammatory response in
control Bcmo1-/- mice may be due to decreased retinoic
acid production. BC supplementation prevents these effects
in the Bcmo1-/- mice, possibly because BC can substitute
for retinoic acid production in a pathway dependent on
beta-carotene dioxygenase 2 (Bdo2), an enzyme with the
ability to asymmetrically cleave BC, thereby generating
b-apocarotenals and b-ionone [42], which can subse-
quently be further metabolized into retinoic acid [43].
Altogether, the altered gene expression of key enzymes for
vitamin A metabolism may result in a changed dietary
vitamin A requirement in Bcmo1-/- mice, which changes
the vitamin A-sufficient control diet for Bcmo1?/? mice, into
a mildly vitamin A-deficient diet for the Bcmo1-/- mice.
We demonstrated an altered BC metabolism in the
Bcmo1-/- mice, which resulted, as intended, in an
increased BC accumulation in lung and serum of the
Bcmo1-/- mice. We also observed some differences in the
gene expression of downstream BC-metabolizing enzymes.
This changed metabolism might be important in under-
standing and investigating the physiological effects of BC
in lung functioning, especially since there are large inter-
human variations in BCMO1 activity due to polymor-
phisms in this gene. There were some interesting,
unexpected changes in BC metabolite levels upon BC
supplementation in Bcmo1-/- mice. First of all, there was
an increase in retinol in lung upon BC supplementation in
Bcmo1-/- mice. This increase in retinol is unlikely to be
originating from metabolized BC. As far we know, only
Bdo2 can serve as a partial alternative to Bcmo1 in BC
metabolism. Bdo2 asymmetrically cleaves BC, thereby
generating an increase in apocarotenals and ultimately into
retinoic acid, which can be degraded by members of the
Cytochrome P450 (CYP) family and in particular CYP26
[44, 45]. Retinol is probably not an intermediate in this
alternative BC metabolism pathway. An increased retinol
absorption in the lung, in combination with the (non-sig-
nificant) decrease in retinol in plasma could theoretically
clarify this observation. However, stimulated by retinoic
acid 6 (Stra6), which is identified as a receptor for the
blood retinol carrier; retinol-binding protein (Rbp) [46],
was not significantly differentially expressed on the
microarrays between the BC-supplemented and control
diet-fed mice. A changed RBP-retinol complex has been
associated with an increased delivery of retinol to different
tissues [46, 47] and might possibly explain our retinol
plasma and lung tissue concentrations. A second never
reported interesting observation herein regarding BC
metabolites in lung tissue was the tighter correlation of BC
with retinyl esters than with retinol in lung tissue of
Bcmo1?/? mice. This implies that BC accumulation tightly
regulates the retinyl ester pool. Lung tissue has relatively
high retinyl ester pools [48]. The main role for retinyl
esters in the lung is to ensure direct retinol delivery when
there is an increased retinol demand in the lung [49],
especially during fetal development. We found a significant
6.5-fold decrease in slope in the correlation of lung BC
with retinyl esters in Bcmo1-/- mice compared to the
Bcmo1?/? mice, which implies decreased conversion effi-
ciency in the Bcmo1-/- mice. This decreased efficiency
was also found in people containing two snp’s in the
BCMO1 gene, resulting in a decreased BCMO1 activity
and a four-fold decreased conversion efficiency of BC as
measured as the triglyceride-rich lipoprotein retinyl pal-
mitate:BC ratio [18]. The surprising findings in BC
metabolites in Bcmo1?/? and Bcmo1-/- mice and the
understanding of these differences are especially important
in understanding the effects of BC in humans, in particular
since downstream BC metabolism is different between
mice and humans, and also between humans.
Since we find inflammatory gene expression to be
increased, the question may be raised whether there was an
unintended infection present solely in the Bcmo1-/- con-
trol mice. There are some reasons to believe that this was
not the case. First, we examined plasma levels of the
cytokines; MCP-1, TNF-a and IL-6, which are highly
increased and detectable upon infection [50]. These levels
were below the limit of detection, which is representative
for an uninfected state. In addition, the Bcmo1-/- mice
both on a control diet and on a BC-supplemented diet were
divided over two independent experiments. The significant
up-regulation of the inflammatory response in the
Bcmo1-/- control mice was similar in both experimental
periods, making infection an unlikely explanation. More-
over, an increased inflammatory response in the lungs is
often seen during vitamin A deficiency. An altered down-
stream BC metabolism in Bcmo1-/- mice, and thereby a
higher vitamin A requirement in Bcmo1-/- mice is there-
fore a likely explanation.
We initiated this study to identify the possible pathways
explaining possible harmful effects of BC. Therefore we
used Bcmo1-/- mice, which are able to accumulate BC
similar to humans. In this study, BC supplementation was
beneficial in Bcmo1-/- mice, since BC supplementation
reduced the inflammatory response in these mice and
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generated a gene-expression pattern more similar to
Bcmo1?/? mice, as has been shown by cluster analysis.
Although BC was beneficial in this model, these data also
demonstrate that BC was able to influence the inflamma-
tory response in the lungs. The harmful effects of BC have
only been reported in smokers and asbestos-exposed sub-
jects (ATBC, CARET). An important difference between
smokers and asbestos-exposed subjects on one hand and
non-smokers on the other, is that smoking causes an
inflammatory response in the lungs, which is shown to be
involved in the onset and progression of carcinogenesis
[51–54]. Since we find differences in downstream
BC-metabolizing enzymes, possible differences in these
enzymes in smokers might give a clue in understanding the
adverse effects of BC in smokers. Microarray analysis of
small airway epithelium of smokers has revealed that
several downstream BC metabolizing enzymes are indeed
differentially expressed. Aldehyde dehydrogenase family 1,
subfamily A3 (ALDH1A3) was five-fold up-regulated and
ADH7 was six-fold up-regulated in smokers compared to
non-smokers [55]. This paper implies that a proper retinoic
acid synthesis is indispensable for correct functioning of
the immune system. It would be of interest to investigate
whether polymorphisms in BC-metabolizing enzymes in
subjects of the ATBC and CARET study alter the lung
cancer risk in smokers upon BC supplementation. Future
studies using Bcmo1-/- mice as well as Bcmo1?/? mice in
combination with BC and smoke or inflammation induction
are necessary to further investigate and explain exact
mechanisms. Since the Bcmo1-/- mice seem to have a
higher dietary need for vitamin A, this concentration
should be increased to avoid effects of vitamin A
deficiency.
All together, our results demonstrate that Bcmo1-/-
mice on a control diet had an increased inflammation in
their lungs, which was decreased to levels as observed in
Bcmo1?/? mice upon BC supplementation. We hypothe-
size that this was due to an increased vitamin A
requirement in Bcmo1-/- due to impaired retinoic acid
synthesis. Since the Bcmo1-/- control mice were mildly
vitamin A-deficient, this study was unable to elucidate BC
accumulation-regulated gene expression. Nevertheless,
these results might be important for the human population
since individuals with polymorphisms in the BCMO1 gene,
with a high population frequency, may also have a higher
risk for vitamin A deficiency, which is still a relatively
frequently occurring state in developing countries as well
as in certain groups of the Western society.
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